Clinical Data GSK hails ‘unprecedented’ cure rates with hep B drug PharmaphorumThe B-Well trials of GSK's bepirovirsen position the antisense drug as a "major step towards a cure for hepatitis B infection," according to experts.Infectious DiseaseRead full story pharminent May 28, 2026 (Last updated: May 28, 2026) Pharmaphorum The B-Well trials of GSK’s bepirovirsen position the antisense drug as a “major step towards a cure for hepatitis B infection,” according to experts. Infectious Disease Read full story Post navigation Previous: AbbVie snags FDA’s first ADC approval for ultra-rare blood cancerNext: France ‘first EU country to cover obesity drugs’ Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026